Cargando…

Step-Therapy Edits for PPIs and COX-2 Drugs - What We Do and Do Not Know

Detalles Bibliográficos
Autor principal:	Curtiss, Frederic R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2004
Materias:	Editorial Subjects In This Issue
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437674/ https://www.ncbi.nlm.nih.gov/pubmed/15298534 http://dx.doi.org/10.18553/jmcp.2004.10.4.356

Ejemplares similares

COPD - Whose Burden, How Large, and What to Do About It?
por: Curtiss, Frederic R.
Publicado: (2005)

Presbyopia: What We Do Know and What We Do Not Know in 2022
por: Grzybowski, Andrzej, et al.
Publicado: (2023)

Clinical, Service, and Cost Outcomes of Drug Coverage Edits and Quanitity Limits
por: Curtiss, Frederic R.
Publicado: (2003)

Pharmacoeconomic Modeling of Drug Therapies for Multiple Sclerosis - Are We Building Houses on Sand?
por: Curtiss, Frederic R.
Publicado: (2007)

What Do We Really Know About VBID? Quality of the Evidence and Ethical Considerations for Health Plan Sponsors
por: Fairman, Kathleen A., et al.
Publicado: (2011)

Outcomes of Sword Swallowing and Pharmaceutical Step-Therapy Interventions
por: Curtiss, Frederic R.
Publicado: (2007)

Hypertension, Prescription Drug Copayments, and Drug Therapy Adherence
por: Curtiss, Frederic R.
Publicado: (2003)

Thymic neuroendocrine neoplasms—what we know, what we don’t know, and what to do about it
por: Lang, Matthias, et al.
Publicado: (2023)

Evidence-Based Medicine: Are SSRIs More Effective Than Placebo and What Length of Therapy is Enough?
por: Curtiss, Frederic R.
Publicado: (2005)

Coffee and digestive cancers—what do we know, and where do we go?
por: Loftfield, Erikka, et al.
Publicado: (2020)

COVID-19 and Dialysis Units: What Do We Know Now and What Should We Do?
por: Ikizler, T. Alp
Publicado: (2020)

Arterial Stiffness—What Do We Know about It and What Do We Expect from This Biomarker?
por: Reiner, Željko
Publicado: (2022)

Monkeypox Outbreaks in Non-Endemic Countries: What Do We Know and What Do We Need?
por: Shamabadi, Ahmad, et al.
Publicado: (2022)

What do we know and when do we know it?
por: Nicholls, Anthony
Publicado: (2008)

Methods to Attain Optimal Outcomes With Lipid-Lowering Drug Therapy
por: Curtiss, Frederic R.
Publicado: (2004)

Quasicrystals: What do we know? What do we want to know? What can we know?
por: Steurer, Walter
Publicado: (2018)

Drug Formulary Decisions - Evaluating the Risks and Benefits of Hormone Replacement Therapy
por: Curtiss, Frederic R.
Publicado: (2004)

Publication ethics – What do we need to know?
por: Mills, Michael
Publicado: (2019)

What Evidence Supports Guidelines for Use of ACE Inhibitors and ARBs in Diabetes?
por: Curtiss, Frederic R.
Publicado: (2006)

What we do and do not know about managing respiratory disease in pregnancy
por: Kent, Brian D.
Publicado: (2022)

PandT Committees - Black Boxes Versus AMCP Format, and What Is the True Cost and Value of Pimecrolimus
por: Curtiss, Frederic R.
Publicado: (2005)

Effects of Physician Report Cards, Knowledge of Drug Prices, and Financial Incentives in Prescription Drug Costs
por: Curtiss, Frederic R.
Publicado: (2003)

3-Tier Drug Benefit Designs Based on Sound Drug Formulary Principles Will Maximize Favorable Outcomes
por: Curtiss, Frederic R.
Publicado: (2004)

Ectopic Calcification: What Do We Know and What Is the Way Forward?
por: Snijders, Birgitta M. G., et al.
Publicado: (2023)

What Do We Know about Suicide Bereavement, and What We Can Do to Help Suicide-Loss Survivors?
por: Levi-Belz, Yossi, et al.
Publicado: (2023)

Preventable Drug-related Morbidity (PDRM)
por: Curtiss, Frederic R.
Publicado: (2003)

Does Persistence With Drugs for Alzheimer's Disease Matter?
por: Curtiss, Frederic R.
Publicado: (2005)

Unraveling the Effects of Tier-Copayment Drug Benefit Designs
por: Curtiss, Frederic R.
Publicado: (2003)

TMAC Savings of 90% for Heartburn Drugs in the United States
por: Curtiss, Frederic R.
Publicado: (2006)

COVID-19 virus and children: What do we know?
por: Morand, A., et al.
Publicado: (2020)

Checkpoint Markers and Tumor Microenvironment: What Do We Know?
por: Ephraim, Ramya, et al.
Publicado: (2022)

Neurologic Complications With Vaccines: What We Know, What We Don't, and What We Should Do
por: Nath, Avindra
Publicado: (2023)

Brian Cox We're doing it not because it's easy, but because it's hard
Publicado: (2009)

Prescription-Equivalent Over-the-Counter Drugs for Allergy, Heartburn, and Cholesterol Reduction
por: Curtiss, Frederic R.
Publicado: (2005)

Contractual Arrangements Between HMOs and Medical Groups to Manage Drug Costs
por: Curtiss, Frederic R.
Publicado: (2003)

The Relative Value of Disease Management Programs Versus Drug Manufacturer Rebates
por: Curtiss, Frederic R.
Publicado: (2003)

COVID-19 and Cardiovascular Surgery. Do We Know What We Are Dealing With?
por: Almeida, Rui M. S., et al.
Publicado: (2021)

Evidence-Based Medicine: Which Drugs Are Truly Contraindicated for Use in Older Adults?
por: Curtiss, Frederic R.
Publicado: (2005)

Multimorbidity: What do we know? What should we do?
por: Navickas, Rokas, et al.
Publicado: (2016)

Prescription Drug Expenditures, Financial Burden, and Health Plan Satisfaction Among Medicare Beneficiaries
por: Curtiss, Frederic R.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_6j2m1e9l2q9rtsog2ja4v6vs1c